[go: up one dir, main page]

RU95110937A - Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения - Google Patents

Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения

Info

Publication number
RU95110937A
RU95110937A RU95110937/04A RU95110937A RU95110937A RU 95110937 A RU95110937 A RU 95110937A RU 95110937/04 A RU95110937/04 A RU 95110937/04A RU 95110937 A RU95110937 A RU 95110937A RU 95110937 A RU95110937 A RU 95110937A
Authority
RU
Russia
Prior art keywords
compounds
intermediates
preparation
acrydine
quinoline
Prior art date
Application number
RU95110937/04A
Other languages
English (en)
Other versions
RU2124006C1 (ru
Inventor
Джон Онмахт Сайрус
Us]
Эми Трейнор Диане
Мэри Форст Дженет
Моррис Стейн Марк
Джозеф Гаррис Роберт
Original Assignee
Зенека Лимитед (GB)
Зенека Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9221989A external-priority patent/GB9221989D0/en
Priority claimed from GB939308065A external-priority patent/GB9308065D0/en
Application filed by Зенека Лимитед (GB), Зенека Лимитед filed Critical Зенека Лимитед (GB)
Publication of RU95110937A publication Critical patent/RU95110937A/ru
Application granted granted Critical
Publication of RU2124006C1 publication Critical patent/RU2124006C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединения общей формулыи их фармацевтически приемлемые соли являются полезными в лечении недержания мочи. Раскрыты также фармацевтические композиции, способы получения соединений указанной формулы и промежуточные продукты.

Claims (1)

  1. Соединения общей формулы
    Figure 00000001

    и их фармацевтически приемлемые соли являются полезными в лечении недержания мочи. Раскрыты также фармацевтические композиции, способы получения соединений указанной формулы и промежуточные продукты.
RU95110937/04A 1992-10-20 1993-10-14 Хинолоновые и акридиноновые соединения, способы их получения и фармацевтическая композиция на их основе RU2124006C1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9221989A GB9221989D0 (en) 1992-10-20 1992-10-20 Heterocyclic derivatives
GB9308065.3 1993-04-20
GB939308065A GB9308065D0 (en) 1993-04-20 1993-04-20 Heterocyclic derivatives
GB9221989.8 1993-04-20
PCT/GB1993/002125 WO1994008966A1 (en) 1992-10-20 1993-10-14 Quinolone and acridinone derivatives for the treatment of urinary incontinence

Publications (2)

Publication Number Publication Date
RU95110937A true RU95110937A (ru) 1997-03-10
RU2124006C1 RU2124006C1 (ru) 1998-12-27

Family

ID=26301823

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95110937/04A RU2124006C1 (ru) 1992-10-20 1993-10-14 Хинолоновые и акридиноновые соединения, способы их получения и фармацевтическая композиция на их основе

Country Status (20)

Country Link
EP (1) EP0665834B1 (ru)
JP (1) JP3315699B2 (ru)
KR (1) KR100296657B1 (ru)
AT (1) ATE201671T1 (ru)
AU (1) AU673696B2 (ru)
CA (1) CA2146763C (ru)
DE (1) DE69330282T2 (ru)
DK (1) DK0665834T3 (ru)
ES (1) ES2160602T3 (ru)
FI (1) FI110940B (ru)
GB (2) GB9318935D0 (ru)
GR (1) GR3036442T3 (ru)
HU (2) HU215386B (ru)
IL (1) IL107287A (ru)
NO (1) NO303222B1 (ru)
NZ (1) NZ256719A (ru)
PT (1) PT665834E (ru)
RU (1) RU2124006C1 (ru)
TW (1) TW261616B (ru)
WO (1) WO1994008966A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2282627C2 (ru) * 2000-07-03 2006-08-27 Орион Корпорейшн Кумариновые производные с подавляющей комт активностью

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407432D0 (en) * 1994-04-14 1994-06-08 Zeneca Ltd Heterocyclic derivative
GB9707695D0 (en) * 1996-08-07 1997-06-04 Hoffmann La Roche Tricyclic dione derivatives
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
CN1158259C (zh) * 1997-12-18 2004-07-21 艾博特公司 钾通道疏通剂
US6642222B2 (en) * 1998-10-28 2003-11-04 Abbott Laboratories Pyrano, piperidino, and thiopyrano compounds and methods of use
JP2002528452A (ja) * 1998-10-28 2002-09-03 アボット・ラボラトリーズ ジヒドロピリジン化合物および使用方法
US6191140B1 (en) * 1998-10-28 2001-02-20 Abbott Laboratories Pyrano, piperidino, and thiopyrano compounds and methods of use
US6518279B2 (en) 1999-03-04 2003-02-11 Abbott Laboratories Cyclopentanone dihydropyridine compounds useful as potassium channel openers
EP1307429B1 (en) 2000-08-02 2007-11-28 AstraZeneca AB Process for asymmetric synthesis of substituted 1,4-dihydropyridines
JP2004505100A (ja) 2000-08-02 2004-02-19 アストラゼネカ・アクチエボラーグ アルファ，ベータ−不飽和ケトンの合成法
FR2856687B1 (fr) * 2003-06-25 2005-09-16 Servier Lab Nouveaux derives de benzo[a]pyrano[3,2-h]acridin-7-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA92008C2 (en) * 2005-05-04 2010-09-27 Н.В. Органон 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
RU2372337C2 (ru) * 2005-05-04 2009-11-10 Н.В. Органон Производные дигидропиридина
UA92009C2 (ru) 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия
UA92007C2 (ru) * 2005-05-04 2010-09-27 Н.В. Органон Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности
JP4869336B2 (ja) * 2005-05-04 2012-02-08 ナームローゼ・フエンノートチヤツプ・オルガノン ジヒドロピリジン誘導体
JP2008540549A (ja) * 2005-05-09 2008-11-20 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能調節用化合物
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
US11976041B1 (en) 2023-10-23 2024-05-07 King Faisal University 9-(5-bromo-2-hydroxyphenyl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione as an antimicrobial compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003148A1 (de) * 1970-01-24 1971-07-29 Bayer Ag Neue 1,4-Dihydropyridinderivate
DE2018738A1 (en) 1970-04-18 1971-10-28 Farbenfabriken Bayer Ag, 5090 Leverkusen Hydrogenated pyridines, quinolines andacridi
DE2310746A1 (de) * 1973-03-03 1974-09-12 Bayer Ag Verfahren zur herstellung von neuen 1,4-dihydrochinolinen sowie ihre verwendung als arzneimittel
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
US5340819A (en) * 1991-10-21 1994-08-23 Imperial Chemical Industries Plc Method for treating urinary incontinence using 9-(3-nitrophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H) acridinedione
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2282627C2 (ru) * 2000-07-03 2006-08-27 Орион Корпорейшн Кумариновые производные с подавляющей комт активностью

Also Published As

Publication number Publication date
NO303222B1 (no) 1998-06-15
HU9302933D0 (en) 1993-12-28
ES2160602T3 (es) 2001-11-16
NO951484D0 (no) 1995-04-19
DE69330282T2 (de) 2002-01-10
NZ256719A (en) 1996-11-26
NO951484L (no) 1995-06-19
RU2124006C1 (ru) 1998-12-27
ATE201671T1 (de) 2001-06-15
GB9318935D0 (en) 1993-10-27
WO1994008966A1 (en) 1994-04-28
EP0665834B1 (en) 2001-05-30
DK0665834T3 (da) 2001-09-10
JP3315699B2 (ja) 2002-08-19
GR3036442T3 (en) 2001-11-30
PT665834E (pt) 2001-11-30
DE69330282D1 (de) 2001-07-05
AU673696B2 (en) 1996-11-21
GB9319938D0 (en) 1993-11-17
HU211741A9 (en) 1995-12-28
IL107287A0 (en) 1994-01-25
TW261616B (ru) 1995-11-01
HU215386B (hu) 1998-12-28
HK1013996A1 (en) 1999-09-17
EP0665834A1 (en) 1995-08-09
CA2146763C (en) 2005-10-04
CA2146763A1 (en) 1994-04-28
AU5154593A (en) 1994-05-09
IL107287A (en) 2000-09-28
KR100296657B1 (ko) 2001-10-24
FI951858A0 (fi) 1995-04-19
FI951858L (fi) 1995-04-19
JPH08502282A (ja) 1996-03-12
HUT70026A (en) 1995-09-28
FI110940B (fi) 2003-04-30

Similar Documents

Publication Publication Date Title
RU95110937A (ru) Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения
SE9902987D0 (sv) Novel compounds
EP1024145A3 (en) Novel azalides and methods of making same
RU95106362A (ru) Производные липопептида, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
ATE94547T1 (de) Pharmazeutische zubereitung enthaltend eine tetrahydropyrrolverbindung als aktiven bestandteil und verfahren zur herstellung dieser tetrapyrrolverbindung.
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
PL358281A1 (en) Novel compounds
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
DK0524781T3 (da) Terapeutiske amider
AU5778090A (en) 11B-aryl-4-estrenes, process for their preparation as well as their use as pharmaceutical agents
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
EP0992509A3 (en) Novel macrolide derivatives
PL342614A1 (en) Anticarcinogenic drugs
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
UA48958C2 (ru) Translated By Plaj9-O-ОКСИМОВЫЕ ПРОИЗВОДНЫЕ ЭРИТРОМИЦИНА А И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ
HUT49614A (en) Process for producing cefalosporin derivatives and pharmaceutical compositions comprising these compounds
HUT51221A (en) Process for producing pharmaceutical compositions comprising 3-demethyl-4-fluoromevalonic acid derivatives and the active ingredients
ATE161006T1 (de) Alkohole als kaliumchannelöffner und zur behandlung der harnincontinenz
HUT77768A (hu) N-szubsztituált azabicikloheptánszármazékok, eljárás előállításukra és alkalmazásuk
GR900100332A (en) Process for preparation of phenoxypropanolamines pharmaceutical compositions containing them and their use as antiobesity agents
EP0379132A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
RU94026088A (ru) Способ лечения шока и способ ингибирования продуцирования альфа фактора некроза опухоли
RU95107706A (ru) Пиридоиндолобензодиазепины и их производные, фармацевтическая композиция антипсихоточеского действия на их основе и способ лечения

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC4A Invention patent assignment

Effective date: 20051004

MM4A The patent is invalid due to non-payment of fees

Effective date: 20071015